Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion. | Aplastic Anemia and MDS International Foundation

Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion.

Journal Title: 
Leuk Res
Author(s): 
Fenaux P, Bowen D, Gattermann N, Hellström-Lindberg E, Hofmann WK, Pfeilstöcker M, Sanz G, Santini V.
Primary Author: 
Fenaux P
Original Publication Date: 
Tuesday, July 6, 2010

Azacitidine is currently the only drug to have shown a significant survival benefit over conventional care regimens in patients with International Prognostic Scoring System (IPSS) intermediate-2 (Int-2) and high-risk myelodysplastic syndromes (MDS), establishing it as an important new treatment for these individuals. However, several aspects of the practical use of azacitidine remain uncertain. This manuscript outlines recommendations discussed by a panel of experts, providing a practical guide for physicians to ensure optimal management of Int-2 and high-risk patients receiving azacitidine.

Bone Marrow Diseases: